<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 165 patients were entered into this study and 140 were evaluate for effects and 165 for toxicities </plain></SENT>
<SENT sid="1" pm="."><plain>Of 39 patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) 21 achieved complete remission (CR), 6 achieved partial remission (PR) with a response rate of 69.2% </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, of 11 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL), one good partial response and 4 partial response were observed (CR + PR:45.5%); of 14 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, one complete response, 4 partial response (CR + PR: 35.7%); of 11 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in T, 3 partial response were observed (response rate: 27.3%) </plain></SENT>
<SENT sid="3" pm="."><plain>Of 13 patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, 4 excellent effect and 7 moderate effect (84.6%) were observed </plain></SENT>
<SENT sid="4" pm="."><plain>Seven of 30 patients with <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> achieved partial response (23.3%) </plain></SENT>
<SENT sid="5" pm="."><plain>Mean dosages of SM-108 until remission were 400-500 mg/m2/day on CMMoL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera and <z:mp ids='MP_0005481'>CML</z:mp>, and 600-800 mg/m2/day on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in T and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In the analysis of adverse effects of SM-108, a subjective side effects including mainly gastrointestinal toxicities were observed in 38 cases (23.0%) of the patients : 26 patients (15.8%) showed objective side effects including <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo>, but these symptoms were transient and not serious </plain></SENT>
<SENT sid="7" pm="."><plain>Our study indicates that SM-108 is useful agent against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, especially CMMoL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in T, <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera and <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
</text></document>